Novartis Aims Double Edged Attack With Galvus And Jalra To Take On Merck's Januvia In India

MUMBAI - The fight for a share of India's growing diabetes drugs market is set to become more fierce as Novartis is exploring an alliance with USV for promoting its type 2 anti-diabetes drug brand Jalra (vildagliptin)